BIOCAUSE HEILEN PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 20.9334 million yuan, a decrease of 71.96%
BIOCAUSE HEILEN PHARMA released its Q3 2025 report, with operating revenue for the first three quarters amounting to 319 million yuan, a year-on-year decrease of 4.52%. The net profit attributable to the parent company was 20.9334 million yuan, a year-on-year decline of 71.96%; the net profit after deducting non-recurring gains and losses was 543,800 yuan, a year-on-year decrease of 99.14%. The basic earnings per share were 0.05 yuan
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 319 million yuan, a year-on-year decrease of 4.52%. The net profit attributable to shareholders of the listed company was 20.9334 million yuan, a year-on-year decrease of 71.96%. The net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 543,800 yuan, a year-on-year decrease of 99.14%. The basic earnings per share were 0.05 yuan
